<DOC>
	<DOC>NCT01356160</DOC>
	<brief_summary>This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection.</brief_summary>
	<brief_title>GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Males and females 1870 years of age Chronic HCV infection Subjects must have liver biopsy results (≤ 2 years prior to Screening) indicating the absence of cirrhosis. Monoinfection with HCV genotype 1 HCV RNA &gt; 10^4 IU/mL at Screening HCV treatment naïve Candidate for PEG/RBV therapy Body mass index (BMI) 1836 kg/m2, inclusive Agree to use two forms of highly effective contraception methods for the duration of the study and for 7 months after the last dose of study medication. Females of childbearing potential must have negative pregnancy test at Screening and Baseline. Pregnant female or male with pregnant female partner Exceed defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH) Diagnosis of autoimmune disease, decompensated liver disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), HIV, hepatitis B virus (HBV), hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers), hemoglobinopathy, retinal disease, or are immunosuppressed. Subjects with current use of amphetamines, cocaine, opiates (e.g., morphine, heroin), or ongoing alcohol abuse are excluded. Patients on stable methadone or buprenorphine maintenance treatment for at least 6 months prior to Screening may be included into the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy HCV RNA</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>GS-5885</keyword>
	<keyword>GS-9451</keyword>
</DOC>